Alaris™ PK Plus Syringe
Directions For Use
Pump MK4
Model: 8005PK201
en
s
Alaris™ PK Plus Syringe Pump
Contents
Introduction ..............................................................................................2
About This Manual ........................................................................................3
TCI Overview ..............................................................................................4
Creating a Data Set ........................................................................................7
Features of the Pump ......................................................................................8
Controls and Indicators ...................................................................................9
Symbol Definitions .......................................................................................10
Main Display Features ....................................................................................11
Operating Precautions ...................................................................................13
Getting Started ..........................................................................................16
Syringe Loading ..........................................................................................18
Starting the Pump ........................................................................................21
Basic Features ............................................................................................23
Operations During Use ...................................................................................25
Alarms and Warnings .....................................................................................27
Prompts .................................................................................................28
Configured Options ......................................................................................29
Specifications ............................................................................................33
Recognised Syringes .....................................................................................36
Associated Products ......................................................................................37
Compatible Extension Sets ...............................................................................38
Maintenance .............................................................................................41
Occlusion Pressure Limits ................................................................................43
IrDA, RS232 and Nurse call Specification ..................................................................44
Trumpet Curves and Start-up Curves .....................................................................46
Profiles from TCI Mode ...................................................................................47
Products and Spare Parts .................................................................................50
Service Contacts .........................................................................................51
Page
1000DF00741 Issue 5
1/52
Alaris™ PK Plus Syringe Pump
Introduction
Introduction
This Directions for use can be used with the Alaris™ PK Plus Syringe Pump MK4.
The Pumps can be identified as MK4 version by the MK4 on
w
The Alaris PK Plus Syringe Pump (hereinafter referred to as Pump) provides the user with an infusion tool for the administration of drugs
for anaesthesia. The embedded software within the Pump is loaded with three compartment pharmacokinetic predictive models and
has 4 modes of operation:
1. Continuous infusion (ml/h)
2. Total Intravenous Anaesthesia (TIVA) mode.
3. Total Intravenous Anaesthesia (TIVA) with TCI predictions mode.
4. TCI Mode
The Alaris PK Plus Syringe Pump has a user friendly interface that displays the infusion rate, the total drug dose delivered, and the
estimated plasma and effect-site concentrations to enable the user to follow the drug prescription information from the relevant
country.
the label on the rear case, see image right, or by verifying the
software version as 3.3.0 or above on power up.
– In this mode the user is able to select the infusion rate and administer bolus doses as required.
– In this mode the user is able to select the infusion rate and administer bolus doses as required. The pharmacokinetic model is
used to estimate the plasma and effect site concentration.
• Plasma target-controlled infusion (TCI).
– In this mode the user selects the desired (target) plasma drug concentration, and the pharmacokinetic model is used to
calculate the infusion rates required to achieve that concentration. A graphic display shows the trajectory of the estimated
plasma and effect site drug concentration over time.
• Effect Site target-controlled infusion (TCI).
– In this mode the user sets the desired effect site target concentration and the pharmacodynamic model is used to calculate
the infusion rates required to achieve that concentration. A graphic display shows the trajectory of the estimated effect site
and plasma concentration over time.
Intended Purpose
The Alaris PK Plus Syringe Pump is intended for use by medical staff for purposes of controlling infusion rate and volume.
Conditions of Use
The Alaris PK Plus Syringe Pump should only be operated by a clinician competent in use of automated syringe pumps and postplacement management of intravenous catheters.
Use of the Alaris PK Plus Syringe Pump does not limit the responsibility of the anaesthetist for drugs administration. It is important that
users operating the Alaris PK Plus Syringe Pump are fully aware of the available literature for any model used in association with a drug
and that they refer to the prescribed information for rate and dosing limits. Pharmacokinetic and Pharmacodynamic Interactions among
anaesthetic drugs are known, but are not taken into account in the calculation of the plasma and effect site concentrations.
The user should be appropriately trained in the use of the Pump and should follow the recommendations of this Direction For Use
(DFU).
In particular, the user must be aware that starting the Pump in a TCI mode will result in the automatic infusion of a pre-calculated bolus
dose followed by an infusion to achieve the selected target concentration. The initial parameter calculations are displayed on screen
prior to starting the infusion. It is thus essential that the user verifies that the patient characteristics and the selected infusion rate or
target concentration conform with the drug prescribing information of the relevant country.
CareFusion has verified the accuracy of the mathematical model implementation as well as pump delivery accuracy - (specification and
accuracy of pump - delivery are available in 'Profiles from TCI Mode' section).
Different drugs are associated with dedicated models – each model consists of a set of standard pharmacokinetic parameters which can
be selected and used by the embedded 3 compartment model used in the Alaris PK Plus Syringe Pump (where use of that drug in TCI
mode is authorised);
Diprivan from ASTRA-ZENECA is the only recommended Propofol formulation to be used in TCI mode as per prescribing information.
This Pump includes the Marsh model for the calculation of the Diprivan infusion rates, and plasma and effect-site concentrations.
When Remifentanil and Sufentanil are used in TCI mode, – the Minto and Gepts models respectively – are used to calculate the required
infusion rates.
1000DF00741 Issue 5
2/52
Alaris™ PK Plus Syringe Pump
About This Manual
CareFusion cannot guarantee the continued system accuracy with other manufacturer’s syringes as identified in the
w
Indications
The Alaris PK Plus Syringe Pump is indicated for the administration of drugs for anaesthesia
Contraindications
The Alaris PK Plus Syringe Pumps are contraindicated for:
‘Recognised Syringes’ table. Manufacturers may change syringe specification significant to system accuracy without
prior notification.
• enteral therapies
• epidural infusion therapies
About This Manual
The user must be thoroughly familiar with the Alaris PK Plus Syringe Pump described in this manual prior to use.
All illustrations used in this manual show typical settings and values which may be used in setting up the functions of the Pump. These
settings and values are for illustrative use only. Where stated, a minimum infusion rate refers to a nominal rate of 1.0ml/h, and an
intermediate infusion rate refers to a nominal rate of 5.0ml/h. The complete range of infusion rates, settings and values are shown in the
'Specifications' section.
It is important to ensure that you only refer to the most recent version of the Directions for Use and Technical Service
w
Conventions used in this manual
BOLD Used for Display names, software commands, controls and indicators referenced in this manual, for
'Single quotes' Used to indicate cross-references made to another section of this manual.
Italics Used to refer to other documents or manuals and also used for emphasis.
w
Manual for your CareFusion products. These documents are referenced on www.carefusion.com. Copies can be
obtained by contacting your local CareFusion representative.
example, Battery Indicator, PURGE, ON/OFF button.
Important Information: Wherever this symbol is shown an Important note is found. These notes highlight
an aspect of use that is important for the user to be aware of when operating the Pump.
1000DF00741 Issue 5
3/52
Alaris™ PK Plus Syringe Pump
TCI Overview
TCI Overview
The dose-response relationship can be divided into three parts: the relationship between administered dose and plasma concentration
(the pharmacokinetic phase), the relationship between effect organ concentration and clinical effect (the pharmacodynamic phase) and
the coupling between pharmacokinetics and dynamics. The ultimate goal when administering a particular dose of a drug is to obtain
the desired clinical effect, for which a specific therapeutic concentration of the drug at the site of action (the receptor) is necessary.
Fig. 1: Schematic representation of the pharmacokinetic and dynamic processes determining the relationship between administered dose
and resulting effect intensity of a drug. Pharmacokinetic factors such as distribution, metabolism, and/or excretion determine the relationship
between drug dose and drug-concentration in the plasma and bio-phase (effect-site). In the bio-phase the drug interacts with the receptor
resulting in the pharmacological effect.
Until recently, when intravenous anaesthetic agents were used for induction or maintenance of anaesthesia, they were administered
either manually (by hand) or by simple infusion pumps (the anaesthetist calculated the infusion according to the body weight
of the patient). Inline measurement of concentrations is not possible, and the polyexponential equations required to predict the
concentrations requires vast computer processing power. Based on the pioneering work of Kruger-Thiemer2 and Schwilden et al.3, the
TCI concept was developed during the 1980’s and early 1990’s, as advances in computer technology made inline predictions of drug
concentrations feasible.
The pharmacokinetic behaviour of most anaesthetic drugs can be described mathematically with a 3-compartment model: usually a
central compartment (V1), a vessel-rich compartment (V2) and a vessel-poor compartment (V3) are described. Transfer of drug between
different compartments (distribution) is described by rate constants (k
by the rate constant k10 (Fig. 2). The aim of TCI techniques is to use pharmacokinetic modelling to calculate the infusion rates required to
achieve a desired plasma concentration. Thus, instead of specifying an infusion rate, the user specifies a "target" concentration, based on
clinical judgement. When a concentration in the plasma compartment is targeted, this is called "open-loop plasma targeted TCI". When a
certain concentration at the effect compartment is targeted, then this is called "open-loop effect-site targeted TCI".
1
, k21, k31 and k13) or clearances. Drug metabolism is described
12
Fig. 2: Schematic representation of the three compartment model used for target-controlled infusions.
For anaesthetic agents the effect-site (or bio-phase) is not the plasma4 but the brain, where concentrations cannot be directly measured.
Until the early 1990’s it was considered that blood-brain equilibration was virtually instantaneous. Early TCI systems were thus all
plasma-targeted. For many drugs the relationship between plasma concentration and clinical effect was described, usually in terms of
the Cp50 or Cp95 (the concentrations required to elicit a specified clinical effect in 50 or 95% of patients respectively). For an example
see Ausems et al.
5
During the 1990’s it was increasingly appreciated that after a change in plasma concentration there is a temporal delay in equilibration
between the plasma and effect-site concentrations. The clinical effect changes in parallel with the effect-site concentration, and so
for most drugs the rate of drug transfer into and from the site of action can be characterized by the time-course of drug effect
6,7
. This
means that the effect can be transferred to concentrations, thereby resulting in a quantitative approach. The concentration at the site of
action is called "the effect-site concentration" and the corresponding compartment8 (see Fig. 3) is called "the effect-site compartment".
Because the actual amount of drug entering the brain is very small, the effect-site compartment can be regarded as having no volume,
the rate constant k1e can be ignored and the rate constant keo can be used to describe the rate of equilibration between the plasma and
effect-site compartments.
1000DF00741 Issue 5
4/52
Alaris™ PK Plus Syringe Pump
Input
TCI Overview
Knowledge of the keo for various agents has made targeting of the effect-site possible. With effect-site targeting the TCI system first
calculates the necessary plasma concentration profile required to achieve the effect-site target as rapidly as possible, and then calculates
the infusion rates required to achieve that plasma concentration profile (Fig 3). Effect Site vs Plasma Concentration will generate a larger
induction dose followed by a pause in the infusion to allow plasma to equilibrate with effect site concentration.
cl2
k
V2
Peripheral
Compartment
Effect
Compartment
Fig. 3: Schematic representation of the concentration-effect relationship.
21
k
12
k
eo
V1 V3
Central
Compartment
Clearance cl1
cl3
k
13
Peripheral
k
31
Compartment
k
10
TCI infusion pumps can provide optimal control of anaesthesia when the three elements mentioned above have been accurately
modelled and described. Firstly, the model that controls the Pump has to work accurately (The models used in the Alaris PK Plus Syringe
Pump are well-validated and accepted). Secondly, the pharmacokinetic parameter set of a particular drug used by the computer model
should match the pharmacokinetics of the patient (it should be remembered that the models described in the literature are based on
"population" data, and apply to an "average" patient. They do not take account of the inter-patient pharmacokinetic variability). Thirdly,
the pharmacodynamics of the administered drug should be well understood to enable the user to select the plasma or effect-site
concentration needed for the required effect (with most anaesthetic agents there is broad inter-patient pharmacodynamic variability,
and so the user needs to match knowledge of the general population pharmacodynamic data with careful observation of the individual
patient to ascertain that individual’s sensitivity to the drug, to enable titration to effect if necessary).
Note: Specific model parameters are available in the "TCI Overview" section or directly on the Pump via the information key when
selecting drugs. Users should refer to the drug- prescribing information to verify that TCI mode is authorised in their respective
countries.
References :
1. Danhof M: Does variability explain (all) variability in drug effects ?, Topics in pharmaceutical science. Edited by Breimer DD, Crommelin DJA, Midha KK. Noordwijk, Amsterdam
Med. Press BV, 1989, pp 573-586
2. Kruger-Theimer E: Continuous intravenous infusion and multicompartment accumulation. Eur J Pharmacol 1968; 4: 317-324
3. Schwilden H: A general method for calculating the dosage scheme in linear pharmacokinetics. Eur J Clin Pharmacol 1981; 20: 379-86
4. Shafer SL: Towards optimal intravenous dosing strategies. Seminars in Anesthesia 1993; 12: 222-234
5. Ausems ME, Hug CC, Jr., Stanski DR, Burm AG: Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. Anesthesiology 1986;
65: 362-73
6. Schnider TW, Minto CF, Stanski DR: The effect compartment concept in pharmacodynamic modelling. Anaesthetic Pharmacology Review 1994; 2: 204-213
7. Shafer SL: Principles of pharmacokinetics and pharmacodynamics., Principles and practice of anesthesiology. 2nd Edition. Edited by Longnecker DE, Tinker JH, Morgan GE.
New York, Mosby-Year Book, 1998, pp 1159- 1210
8. Shafer SL, Gregg KM: Algorithms to rapidly achieve and maintain stable drug concentrations at the site of drug effect with a computer-controlled infusion pump. J
Pharmacokinet Biopharm 1992; 20: 147-69
TCI Precautions
When first starting the infusion the pharmacokinetic / pharmacodynamic models within the Alaris PK Plus Syringe Pump are
reset to zero. Therefore, for any reason, if the Pump is switched off during the surgical procedure all current pharmacokinetic /
pharmacodynamic model information will be lost. Under such circumstances switching the Pump off and on and restarting the infusion
whilst the patient contains a significant residual drug dose could result in an over-infusion and, therefore, the Pump should not be
restarted in TCI mode.
1000DF00741 Issue 5
5/52
Pharmacokinetic models in Alaris PK Plus Syringe Pump and their parameters
Drug: Diprivan Model: Marsh (weight adjusted)
Age Limit: 16 years upwards
Unit of Plasma Concentration: µg/ml
Max. Plasma Concentration: 15 µg/ml
Vc = 0.228 x mass (litres x kg-1)
k10 = 0.119 minutes
k12 = 0.112 minutes
k13 = 0.0419 minutes
k21 = 0.055 minutes
k31 = 0.0033 minutes
keo = 0.26 minutes
Reference from the literature: Marsh et al.: Brit J Anaesth 1991, 67, 41-48
Drug : Remifentanil Model: Minto
Age Limit: 12 years upwards
Unit of Plasma Concentration: ng/ml
Max. Plasma concentration: 20 ng/ml
Vc = 5.1 - 0.0201 x (age-40) + 0.072 x (lbm-55)
V2 = 9.82 - 0.0811 x (age-40) + 0.108 x (lbm-55)
V3 = 5.42
cl1 = 2.6 - 0.0162 x (age - 40) + 0.0191 x (lbm - 55)
cl2 = 2.05 - 0.0301 x (age - 40)
cl3 = 0.076 - 0.00113 x (age - 40)
k
= cl1 / Vc
10
k12 = cl2 / Vc
k
= cl3 / Vc
13
= cl2 / V2
k
21
k31 = cl3 / V3
keo = 0.595 - 0.007 x (age - 40)
Reference from the literature : Minto et al.: Anesthesiology 1997, 86, 10 - 33
-1
-1
-1
-1
-1
-1
Alaris™ PK Plus Syringe Pump
TCI Overview
Drug : Sufentanil Model: Gepts (not weight adjusted)
Age Limit: 12 years upwards
Unit of Plasma Concentration: ng/ml
Max. Plasma concentration: 2 ng/ml
Vc = 14.3 l
k
= 0.0645 minutes
10
k12 = 0.1086 minutes
k13 = 0.0229 minutes
k21 = 0.0245 minutes
k31 = 0.0013 minutes
-1
-1
-1
-1
-1
Reference from the literature : Gepts et al.: Anesthesiology 1995, 83, 1194-1204
Additional :
k
calculated with time to peak effect 5.6 minutes (keo = 0.17559 minutes-1) (reference: Shafer et al Anesthesiology. 1991 Jan;74(1):53-
eo
63)
1000DF00741 Issue 5
6/52
Alaris™ PK Plus Syringe Pump
Creating a Data Set
Creating a Data Set
To fully utilise the Alaris PK Plus Syringe Pump a Data Set will need to be developed, reviewed, approved, released, uploaded and
verified according to the following process. Refer to the Alaris PK Editor Software Directions for Use (1000CH00016) for further details
and operating precautions.
1. Create Master Lists (Using Alaris PK Editor Software)
• Master Drugs* A list of drug names and standard concentrations. These may be for TIVA use or
may have an associated PK/PD model for TCI use.
• Alaris PK Plus Syringe Library Configure syringes enabled for use
2. Create Profile (Using Alaris PK Editor Software)
• Profile Drugs* Drugs and concentrations for this profile with defaults, minimum and
maximum limits and targets and occlusion level.
• Pump Configuration** Pump configuration settings and general options.
3. Review, Approve and Release (Using Alaris PK Editor Software)
• Review and Approve Entire Data Set Report to be printed, reviewed and signed as proof of approval
by an authorised person according to Hospital protocol. Signed printout to be
kept safe for use during verification procedure.
• Release Data Set status to be promoted to Released (password is required).
4. Upload Data Set to Alaris PK Plus Syringe Pump (Using Alaris PK Editor Transfer Tool)
5. Verify Data Set Upload
• First or Individual Pump Verification On completion of upload record CRC (Cyclic Redundancy Check) number
shown on the Alaris PK Plus Syringe Pump.
Download the Data Set from the Pump using the Alaris PK Verification Tool.
Compare Data Set downloaded with the approved signed Data Set printout.
Reviewer should sign the printout and also record the CRC number on the
printout as record.
• Subsequent Pump Verification On subsequent uploads of the Data Set compare CRC number on the Pump
with CRC number recorded on First Pump Verification.
6. Switch the Pump on and verify that the start-up splash screen displays the correct data set name and version. The Pump is now
ready to use.
w
*Drug parameters have to be in accordance to local protocols and prescribed information.
Data set transfers should only be performed by qualified technical personnel.
** See important note in Configured Options section.
1000DF00741 Issue 5
7/52
Features of the Pump
Alaris™ PK Plus Syringe Pump
Features of the Pump
ON/OFF
RUN
Display
Release lever
for MDI
High visibility
Alarm Indicator
PURGE/BOLUS
MUTE
PRESSURE
OPTION
Finger
Grips
Extension set
hook
Rating Plate (see Symbol Definitions for an
explanation of the symbols used)
Release
lever for
Rotating
Cam
HOLD
M
e
Shelf for chevron
keys and softkeys
d
i
c
a
l
D
e
v
i
c
e
I
n
t
e
r
f
a
c
e
(
M
D
I
Syringe Clamp
)
Positive Plunger
Grippers
Rotating Cam to
lock on to horizontal
rectangular bars
Carrying
Handle
IR Communications
port
Potential
Equalisation (PE)
connector
1000DF00741 Issue 5
Folded Pole
Clamp
8/52
RS232
Connector
Extension set
hook
Controls and Indicators
Controls:
Symbol Description
ON/OFF button - Press once to switch the Pump on. Press and hold down for 3 seconds to switch the
Pump off.
a
Note: Pump can only be switched off at specific stages of operation, see 'Power Down Sequence'
section in Configured Options for further details.
Alaris™ PK Plus Syringe Pump
Controls and Indicators
b
h
R
i
d
RUN button - Press to start the infusion. The green LED will flash during infusion.
HOLD button - Press to put the infusion on hold. The amber LED will be lit while on hold.
MUTE button - Press to silence alarm for two minutes.
Note: Callback alarm only:
– The two minutes silence can be configured using the Alaris PK Editor Software.
– when not in alarm press and hold until three audible beeps are sounded for 60 minutes
silence
PURGE/BOLUS button - Press to access PURGE or BOLUS softkeys. Press and hold down softkey to
operate.
PURGE the extension set during set up.
• Pump is on hold
• Extension set must not be connected to the patient
• Volume Infused (VI) is not added
BOLUS - fluid or drug delivered at an accelerated rate.
• Pump is infusing
• Extension set is connected to the patient
• VI is added
OPTION button - Press to access optional features, see 'Basic Features' section.
e
PRESSURE button - Use this button to display the pumping pressure and alarm level.
f
CHEVRON keys - Double or single for faster/slower increase or decrease of values shown on display.
BLANK SOFTKEYS - Use in conjunction with the prompts shown on the display.
g
Indicators:
Symbol Description
BATTERY indicator - When illuminated the Pump is running on the internal battery. When flashing the
j
S
battery power is low with less than 30 minutes of use remaining.
AC POWER indicator - When illuminated the Pump is connected to an AC Power Supply and the battery
is being charged.
1000DF00741 Issue 5
9/52
Symbol Definitions
Labelling Symbols:
Symbol Description
Alaris™ PK Plus Syringe Pump
Symbol Definitions
w
x
y
l
IP32
r
s
T
t
U
Consult accompanying documents.
Potential Equalisation (PE) Connector
RS232/Nurse call Connector
Defibrillation-proof type CF applied part (Degree of protection against electrical shock)
Protected against direct sprays of water up to 15° from vertical and protected against solid objects greater than
2.5mm.
Note: IP33 applies if AC power cable retainer kit, part number 1000SP01294, is fitted.
Alternating Current
Device complies with the requirements of Council Directive 93/42/EEC as amended by 2007/47/EC.
Date of Manufacture
Manufacturer
Not for Municipal Waste
W
0°C
EC REP
Fuse Rating
+40°C
Operating Temperature Range - Pump can be used between 0 and 40 degrees centigrade.
Authorised representative in the European Community
1000DF00741 Issue 5
10/52
Main Display Features
CONFIRM TIME
BMI 21.6
TIVA Mode
Pump Status
Drug Name and
Concentration
Alaris™ PK Plus Syringe Pump
Main Display Features
Pressure Information
Flow Rate and
Dose Rate
Dose and
Volume Infused
TCI Mode
Pump Status
Plasma
Concentration
Plasma Target
Initial Induction
Dose
Initial Induction
Rate
Initial Induction
Volume
TCI Mode - MORE Information Screen
Selecting the MORE softkey will display the following additional information:
Drug Name
and Model
Drug Name and
Concentration
Induction
Duration
Time of
Induction
Operations
During Use
Pause Before
Maintenance
Initial Maintenance
Rate
Volume and
Dose InfusedElapsed Time
Patient Parameters Time to End of Infusion
at Current Rate
Press the BACK softkey to return to the TCI screen. The display will automatically revert to the TCI screen after approximately 20 seconds.
1000DF00741 Issue 5
Decrement
Time
Decrement
Concentration
11/52
Screen Icons
Symbol Description
Alaris™ PK Plus Syringe Pump
Main Display Features
l
N
C
D
E
F
TIME REMAINING DISPLAY icon - Indicates time before syringe will require replacing.
BATTERY icon - Indicates battery charge level to highlight when the battery will require recharging. This can
be enabled/disabled with the Alaris PK Editor Software
Induction Phase Dose (Displayed on protocol confirmation screen)
Duration of Induction Phase (Displayed on protocol confirmation screen)
Duration of Hands Free Bolus (Displayed in bolus set-up screen)
Maintenance Phase Dose Rate (Displayed on protocol confirmation screen)
SOFT ALERT - Indicates the Pump is running at a rate above (pointing up) or below (pointing down) a Soft
Alert. (Number of arrows vary depending on drug name length)
LIMIT WARNING - Indicates the setting entered is under or exceeds a Soft Alert or setting entered is not
permitted as it exceeds a Hard Limit.
DOWN MODE - Infusion status indicating that the target concentration is below current concentration.
1000DF00741 Issue 5
12/52
Operating Precautions
Disposable Syringes and Extension Sets
m
n
o
I
• The Pump has been calibrated for use with single-use disposable syringes. To ensure correct and accurate
operation, only use 3 piece Luer lock versions of the syringe make specified on the Pump or described in
this manual. Use of non-specified syringes or extension sets may impair the operation of the Pump and
the accuracy of the infusion.
• Uncontrolled flow or syphoning may result if the syringe is located incorrectly in the Pump, or if it is
removed from the Pump before the extension set is properly isolated from the patient. Isolation may
include closing a tap in the patient line or activating a flow stop clamp.
• Secure the extension set to the Pump using the extension set hook at the rear of the Pump. This provides
protection against accidental dislodging of the syringe from the Pump.
• When combining several apparatus and/or instruments with extension sets and other tubing, for example
via a 3-way tap, the performance of the Pump may be impacted and should be monitored closely.
• Always clamp or otherwise isolate the patient line before unclamping or removing a syringe from the
Pump. Failure to do so may result in unintended administration.
Mounting the Pump
• When more than one pump is being used on a patient, those containing high risk, critical medications
must be positioned as close to the patient's heart level as possible to avoid the risk of variations in flow or
siphoning.
• Raising a Pump whilst infusing may result in a bolus of the infusate, whereas lowering a Pump whilst
infusing may result in a delay in the infusion (an underinfusion).
• Do not mount the Pump in a vertical position with the syringe pointing upwards as this could lead to
an infusion of air which may be in the syringe. To protect against the introduction of air the user should
regularly monitor the progress of the infusion, syringe, extension line and patient connections and follow
the priming procedure specified herein.
Alaris™ PK Plus Syringe Pump
Operating Precautions
J
Operating Environment
• Intended environments include intensive care and operating rooms. Ensure that the Pump is
appropriately attached using the provided pole clamp. If the Pump is dropped or experiences any
severe physical disturbances, arrange a thorough inspection by Qualified Service Personnel as soon as is
practically possible. The Pump may be used as long as the temperature is within the specified range as
stated in the 'Specifications' section and on the Pump label.
• When using any infusion pump in conjunction with other pumps or devices requiring vascular access,
extra care is necessary. Adverse delivery of medication or fluids can be caused by the substantial variation
in pressures created within the infusion system by such pumps. Typical examples of those pumps are
used during dialysis, bypass or cardiac assist applications.
• The Pump is suitable for use in hospital and clinical environments other than domestic establishments
and those directly connected to the public single phase AC Power Supply network that supplies buildings
used for domestic purposes. (Consult Technical Service Manual, Qualified Service Personnel or CareFusion
for further information).
• The Pump is not intended to be used in the presence of a flammable anaesthetic mixture with air or
oxygen or nitrous oxide.
Operating Pressure
• This is a positive pressure Pump designed to achieve very accurate fluid administration by automatically
compensating for resistance encountered in the infusion system.
• The pumping pressure alarm system is not designed to provide protection against, or detection of, IV
complications which can occur.
Alarm Conditions
• Several alarm conditions detected by this Pump will stop the infusion and generate visual and audible
alarms. Users must perform regular checks to ensure that the infusion is progressing correctly and no
alarms are operating.
1000DF00741 Issue 5
13/52
A
V
L
Alaris™ PK Plus Syringe Pump
Operating Precautions
Hazards
• An explosion hazard exists if the Pump is used in the presence of flammable anaesthetics. Exercise care to
locate the Pump away from any such hazardous sources.
• Dangerous Voltage: An electrical shock hazard exists if the Pump’s casing is opened or removed. Refer all
servicing to Qualified Service Personnel.
• When connected to an external power source, a three-wire (Live, Neutral, Earth) supply must be used. If
the integrity of the external protective conductor in the installation or its arrangement is in doubt, the
Pump should be operated from the battery.
• Do not open the RS232/Nurse Call protective covering when not in use. Electrostatic discharge (ESD)
precautions are required when connecting RS232/Nurse Call. Touching the pins of the connectors may
result in ESD protection failure. It is recommended that all actions must be taken by appropriately trained
personnel..
• If the Pump is dropped, subjected to excessive moisture, fluid spillage, humidity or high temperature, or
otherwise suspected to have been damaged, remove it from service for inspection by Qualified Service
Personnel. When transporting or storing the Pump, use original packaging where possible, and adhere
to temperature, humidity and pressure ranges stated in the 'Specifications' section and on the outer
packaging.
• The embedded Pump software incorporates limits and Pump configuration parameters. Qualified
personnel must ensure the appropriateness of the limits, the compatibility of the drugs, and the
performance of each Pump, as part of the overall infusion. Potential hazards include drug interactions,
and inappropriate delivery rates and pressure alarms.
• Warning: Alaris Syringe Pumps should not be modified or altered in any way, except where explicitly
directed or authorised by CareFusion. Any use of Alaris Syringe Pumps which have been altered or
modified otherwise than in strict application of directions provided by CareFusion, is at your sole risk, and
CareFusion does not provide any warranty for or endorsement on any Alaris Syringe Pump that has been
so modified or altered. CareFusion product warranty shall not apply in the event the Alaris Syringe Pump
has suffered damage or premature wear, or malfunctions or otherwise operates incorrectly, as a result of
unauthorised modification or alteration of the Alaris Syringe Pump.
1000DF00741 Issue 5
14/52
M
MR
K
Alaris™ PK Plus Syringe Pump
Operating Precautions
Electromagnetic Compatibility and Interference
• The Pump is protected against the effects of external interference, including high energy radio frequency
emissions, magnetic fields and electrostatic discharge (for example, as generated by electrosurgical and
cauterising equipment, large motors, portable radios, cellular telephones etc.) and is designed to remain
safe when unreasonable levels of interference are encountered.
• Therapeutic Radiation Equipment: Do not use the Pump in the vicinity of any Therapeutic Radiation
Equipment. Levels of radiation generated by the radiation therapy equipment such as Linear Accelerator,
may severely affect functioning of the Pump. Please consult manufacturer’s recommendations for safe
distance and other precautionary requirements. For further information, please contact your local
CareFusion representative.
• Magnetic Resonance Imaging (MRI): The Pump contains ferromagnetic materials which are susceptible
to interference with magnetic field generated by the MRI devices. Therefore, the Pump is not considered
an MRI compatible pump as such. If use of the Pump within an MRI environment is unavoidable, then
CareFusion highly recommends securing the Pump at a safe distance from the magnetic field outside
the identified ‘Controlled Access Area’ in order to evade any magnetic interference to the Pump; or
MRI image distortion. This safe distance should be established in accordance with the manufacturer's
recommendations regarding electromagnetic interference (EMI). For further information, please refer to
the product Technical Service Manual (TSM). Alternatively, contact your local CareFusion representative for
further guidance.
• Accessories: Do not use any non-recommended accessory with the Pump. The Pump is tested and
compliant with the relevant EMC claims only with the recommended accessories. Use of any accessory,
transducer or cable other than those specified by CareFusion may result in increased emissions or
decreased pump immunity.
• This Pump is a CISPR 11 Group 1 Class A device and uses RF energy only for its internal function in
the normal product offering. Therefore, its RF emissions are very low and are not likely to cause any
interference with the nearby electronic equipment. However, this Pump emits a certain level of
electromagnetic radiation which is within the levels specified by IEC/EN60601-1-2 and IEC/EN60601-2-
24. If the Pump interacts with other equipment, measures should be taken to minimise the effects, for
instance by repositioning or relocation.
• In some circumstances the Pump may be affected by an electrostatic discharge through air at levels close
to or above 15kv; or by radio frequency radiation close to or above 10v/m. If the Pump is affected by
this external interference the Pump will remain in a safe mode; the Pump will duly stop the infusion and
alert the user by generating a combination of visual and audible alarms. Should any encountered alarm
condition persist even after user intervention, it is recommended to replace that particular Pump and
quarantine the Pump for the attention of Qualified Service Personnel. (Consult Technical Service Manual
for further information).
1000DF00741 Issue 5
15/52
Alaris™ PK Plus Syringe Pump
Getting Started
Getting Started
Initial Set-up
Before operating the Pump read this Directions For Use manual carefully.
w
1. Check that the Pump is complete, undamaged and that the voltage rating specified on the label is compatible with your AC Power
Supply.
2. Items supplied are:
• Alaris PK Plus Syringe Pump
• User Support CD (Directions For Use)
• AC Power Cable (as requested)
• Protective Packaging
3. Connect the Pump to the AC Power Supply for at least 2½ hours to ensure that the internal battery is charged (verify that the S is
lit).
Language Selection
1. On initial start-up the Pump will display the Select Language screen.
2. Select the required language from the list displayed using the
3. Press the OK softkey to confirm your selection.
f keys.
w
• The Pump will automatically operate from its internal battery if the Pump is switched on without being connected
to the AC Power Supply.
• Should the Pump fail to perform correctly, replace in its original protective packaging, where possible and contact
Qualified Service Personnel for investigation.
1000DF00741 Issue 5
16/52
Loading...